Eli Lilly and Co

US FDA approved Zepbound, a weight-loss drug by Eli Lilly, for treating moderate to severe obstructive sleep apnoea in obese adults. Zepbound, already approved for obesity with related conditions, works by reducing appetite and food intake, improving OSA through weight loss. Clinical trials showed significant reduction in sleep apnea episodes, with nearly half of patients no longer experiencing OSA symptoms.

The FDA approved Zepbound, a weight-loss drug, for treating moderate to severe obstructive sleep apnea in obese individuals. It should be used with a reduced-calorie diet and increased physical activity. Clinical trials showed significant improvements in breathing disruptions and weight loss, with common side effects being gastrointestinal events.

FDA expands Eli Lilly's Zepbound approval to treat moderate to severe obstructive sleep apnea in obese patients, the first medication for the condition. Insurance providers, including Medicare, may cover it. Zepbound users experienced fewer breathing interruptions and weight loss, with up to half no longer showing symptoms after a year.

Novo Nordisk's CagriSema, an obesity therapy, showed a 20.4% weight reduction in REDEFINE 1 study, falling short of the expected 25%. Despite data suggesting a 22.7% reduction assuming full adherence, shares fell 20.7% due to concerns over side effects and performance compared to Eli Lilly's Zepbound. Future trials and regulatory filings for CagriSema are anticipated.

Naloxone essential for reversing opioid overdoses; FDA approves Vertex's cystic fibrosis treatment and Eli Lilly's Zepbound for weight loss and sleep apnea.

FDA approves Zepbound for treating moderate-to-severe obstructive sleep apnea and obesity. Trials show Zepbound reduces breathing disruptions and aids weight loss, but side effects include digestive issues and potential thyroid tumors.

In 2024, India's CDSCO approved 19 new drugs, including next-gen therapies for chronic diseases by global majors. Eli Lilly's Mounjaro for diabetes/obesity, Orchid Pharma's Enmetazobactam for resistant bacteria, Cipla's plazomicin for UTIs, Sun Pharma's Etifoxine for anxiety, Dr Reddy's Elobixibat for constipation, and Zydus/Lupin's Vonoprazan for stomach ulcers were notable. New cancer drugs like Eli Lilly's Retevmo and Zydus's nelarabine were also approved.

The FDA approved Eli Lilly's Zepbound (tirzepatide) for treating moderate to severe obstructive sleep apnea (OSA) in adults with obesity, based on SURMOUNT-OSA trials showing significant reductions in apnea-hypopnea index (AHI) and substantial weight loss. Zepbound, which reduces appetite and food intake, offers a new non-invasive treatment option for OSA, a condition affecting 30 million Americans but significantly underdiagnosed. Common side effects include gastrointestinal issues, and patients with a history of medullary thyroid carcinoma should avoid the drug.

Novo Nordisk's CagriSema trial disappoints, causing $125B market value drop. Competition in weight-loss drug market intensifies with generic versions emerging. FDA approval of Vertex Pharma's cystic fibrosis treatment highlights pharmaceutical innovation.